Dohrn, Maike F. http://orcid.org/0000-0002-5320-9807
Auer-Grumbach, Michaela
Baron, Ralf
Birklein, Frank
Escolano-Lozano, Fabiola
Geber, Christian
Grether, Nicolai
Hagenacker, Tim
Hund, Ernst
Sachau, Juliane
Schilling, Matthias
Schmidt, Jens
Schulte-Mattler, Wilhelm
Sommer, Claudia
Weiler, Markus
Wunderlich, Gilbert
Hahn, Katrin
Article History
Received: 7 May 2020
Revised: 27 May 2020
Accepted: 29 May 2020
First Online: 4 June 2020
Compliance with ethical standards
:
: MFD, FB, FEL, CG, NG, EH, MS, JSch, WSM, CS, MW, GW, and KH received financial reimbursement for consulting and advisory board activities and/or travel support by Akcea, Alnylam, and Pfizer. MFD further received research funding by Pfizer (ASPIRE 2018) and is currently receiving a scholarship for a research fellowship by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG). RB reports grants/research support from Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma Research GmbH und Co. KG., Novartis Pharma GmbH, Alnylam Pharmaceuticals Inc. and Zambon GmbH and as part of the EU Project: “Europain” (115007), the DOLORisk project (633491), the IMI Paincare (777500), the German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Frühdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), and German Research Network on Neuropathic Pain (01EM0903). He has received speaker fees from Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma, Sanofi Pasteur, Medtronic Inc. Neuromodulation, Eisai Co.Ltd., Lilly GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Astellas Pharma GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer-Schering, MSD GmbH, Seqirus Australia Pty. Ltd, Novartis Pharma GmbH, TAD Pharma GmbH, Grünenthal SA Portugal, Sanofi-Aventis Deutschland GmbH, Agentur Brigitte Süss, Grünenthal Pharma AG Schweiz, and Grünenthal B.V. Niederlande. He has also been a consultant for Pfizer Pharma GmbH, Genzyme GmbH, Grünenthal GmbH, Mundipharma Research GmbH und Co. KG, Allergan, Sanofi Pasteur, Medtronic, Eisai, Lilly GmbH, Boehringer Ingelheim Pharma GmbH&Co.KG, Astellas Pharma GmbH, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogenidec, AstraZeneca GmbH, Merck, Abbvie, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd, Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Astellas Pharma Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc. USA, Theranexus DSV CEA Frankreich, Abbott Products Operations AG Schweiz, Bayer AG, Grünenthal Pharma AG Schweiz, Mundipharma Research Ltd. UK, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH & Co. KG, Air Liquide Sante International Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd, Hexal AG, Ethos Srl Italien, and Janssen. TH and MAG report research support from speaker honoraria from Pfizer, adboard and speaker honoraria from Akcea Therapeutics, adboard, speaker honoraria and research support from Biogen, Sanofi-Genzyme and Roche, adboard and speaker honoraria from CSL Behring and Novartis. JS reports personal fees from Grünenthal GmbH and travel support from Alnylam Pharmaceuticals Inc. and Pfizer.